Overview

Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)

Status:
RECRUITING

Trial end date:
2030-04-01

Target enrollment:

Participant gender:

Summary

The goal of this study is to see if the combination of immunotherapy agents botensilimab and balstilimab is safe and effective in participants with metastatic non-small cell lung cancer (NSCLC) as a first-line treatment.

Phase:

PHASE2

Details

Lead Sponsor:

Immune Oncology Research Institute

Collaborator:

Agenus Inc.

Treatments:

balstilimab